Inclusion Criteria:

* Completion of a Cytokinetics trial investigating CK-3773274
* LVEF ≥55% at the Screening Visit

Exclusion Criteria:

* Has received treatment with mavacamten: (a) within 56 days prior to dosing and (b) has not received approval for participation from the Medical Monitor.
* Has participated in another investigational device or drug study or received an investigational device or drug \< 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
* Since completion of a previous trial of CK-3773274 has:

* Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) \<30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) \<100 bpm and/or rhythm is stable \>30 days
* Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation) since the completion of a prior trial of CK-3773274.
* Had a confirmed LVEF \<40% with an associated dose interruption during participation in a prior study with CK-3773274
* History of appropriate ICD shock within 30 days prior to screening

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/30/2024. Questions regarding updates should be directed to the study team contact.